Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
Titel:
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
Auteur:
Alves, Katia Kotloff, Karen McClelland, R Scott Kouassi, Alex Plested, Joyce S Kalkeri, Raj Zhu, MingZhu Cloney-Clark, Shane Cai, Zhaohui Smith, Katherine Kaba, Muneer Nelson, Joy Hammershaimb, E Adrianne Mallory, Raburn M Noriega, Fernando